Calton & Associates’s Impax Laboratories, Inc. IPXL Stock Holding History

Calton & Associates’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-25	Closed	–	–	1499
2017 Q4	$0	Buy	+25	New	+$458	﹤0.01%	1546

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Calton & Associates's IPXL Position: Q1 2018 in Review

Calton & Associates sold out of Impax Laboratories, Inc. (IPXL) in Q1 2018, closing a stake of 25 shares.

Calton & Associates first reported a position in IPXL in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 188 funds tracked by Wall St. Rank hold IPXL as of Q1 2018.

Calton & Associates reported no remaining Impax Laboratories, Inc. position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 25 Impax Laboratories, Inc. shares in Q1 2018.
Calton & Associates first reported a position in Impax Laboratories, Inc. in Q4 2017 and held it in 1 quarter.
Calton & Associates's Impax Laboratories, Inc. position peaked at $0 in Q4 2017.
188 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.